Targeting the AXL pathway: a promising strategy for pulmonary fibrosis
- PMID: 40473304
- DOI: 10.1183/13993003.00114-2025
Targeting the AXL pathway: a promising strategy for pulmonary fibrosis
Conflict of interest statement
Conflict of interest: J.L. Larson-Casey has no potential conflicts of interest to disclose. A.B. Carter has a patent issued (14262448: Methods to modulate Rac1 import and to treat pulmonary fibrosis).
Comment on
-
Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation.Eur Respir J. 2025 Jun 5;65(6):2400615. doi: 10.1183/13993003.00615-2024. Print 2025 Jun. Eur Respir J. 2025. PMID: 39788632 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous